Drug Trial Radar · NCT06109948
Study to Assess the Safety, Tolerability, PK and PD of ABX1100
Last checked: Nov 20, 2026Latest source record: May 7, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
46
Actual
Start
Oct 19, 2023
Primary completion
Feb 13, 2026
Study completion Feb 13, 2026
Sponsor
- Lead sponsor
- Aro BiotherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Oct 31, 2023
Design
- Study type
- Interventional
- Phase
- Early phase 1
- Allocation
- Randomized
- Model
- Single group
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Study ABX1100-1001 is a first-in-human (FIH), phase 1 study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of a single ascending dose (SAD) and multiple doses (MD) of ABX1100 administered intravenously to healthy participants and patients with LOPD. * Part A features a SAD study with a double-blind, placebo-controlled, randomized design in NHVs involving 3 cohorts (A1-A3). This Part also includes a single dose, open-labeled cohort (A4) in NHVs which will commence after cohorts A1-3. * Part B is a MD, double-blind, placebo-controlled, randomized design in NHVs. The MD Part B will commence after completion of Cohorts A1, A2 and A3 in the SAD Part A and SRC review of these 3 cohorts. * Part C opened for enrollment after the Safety Review Committee (SRC) review of safety, PK and PD data from both Part A and Part B. Part C is a MD, open-label design in patients with Late-Onset Pompe Disease.
Conditions
- Healthy
- Late Onset Pompe Disease
Interventions
ABX1100 injection for IV infusionDrug
Centyrin protein-siRNA conjugate
Placebo injection for IV infusionDrug
placebo saline injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of subjects with treatment-emergent adverse events (TEAEs)Time frame: up to 20 weeks
Locations
5 sites in 2 countries. Site status is shown where the registry gives one.
UCI
Orange, California
Washington University School of Medicine
St Louis, Missouri
Lysosomal and Rare Disorders Research and Treatment Center, Inc
Fairfax, Virginia
MAGIC clinic
Calgary, Alberta, Canada
McMaster University
Hamilton, Ontario, Canada
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.